Cargando…

Different circulating biomarkers in women and men with paroxysmal atrial fibrillation: results from the AF-RISK and RACE V studies

AIMS: The clinical risk profile of atrial fibrillation (AF) patients is different in men and women. Our aim was to identify sex differences in blood biomarkers in patients with paroxysmal AF. METHODS AND RESULTS: Sex differences in 92 blood biomarkers were measured in 364 patients included in our di...

Descripción completa

Detalles Bibliográficos
Autores principales:	De With, Ruben R, Artola Arita, Vicente, Nguyen, Bao-Oanh, Linz, Dominik, Ten Cate, Hugo, Spronk, Henri, Schotten, Ulrich, Jan van Zonneveld, Anton, Erküner, Ömer, Bayón, M Agustina, Schmidt, Anders S, Luermans, Justin G L M, Crijns, Harry J G M, Van Gelder, Isabelle C, Rienstra, Michiel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824515/ https://www.ncbi.nlm.nih.gov/pubmed/34329401 http://dx.doi.org/10.1093/europace/euab179

Ejemplares similares

Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study
por: Artola Arita, Vicente, et al.
Publicado: (2023)

Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V
por: De With, Ruben R, et al.
Publicado: (2020)

Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fibrillation
por: Nguyen, Bao-Oanh, et al.
Publicado: (2023)

Stroke risk in patients with device-detected atrial high-rate episodes
por: Erküner, Ö., et al.
Publicado: (2017)

Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
por: van de Lande, Martijn E, et al.
Publicado: (2023)

Increased plasma levels of NT-proBNP, Troponin T and GDF-15 are driven by persistent AF and associated comorbidities: Data from the AF-RISK study
por: Meems, L.M.G., et al.
Publicado: (2022)

Number of comorbidities is associated with symptom severity and arrhythmia progression in paroxysmal atrial fibrillation - Data from the RACE V study
por: Van De Lande, M E, et al.
Publicado: (2023)

Reappraisal of Atrial fibrillation: interaction between hyperCoagulability, Electrical remodelling and Vascular destabilisation in the progression of AF (RACE V) Tissue Bank Project: study design
por: Gilbers, M. D., et al.
Publicado: (2021)

Brady- and tachyarrhythmias in paroxysmal atrial fibrillation: results from long-term continuous electrocardiographic monitoring in RACE V
por: Park Frausing, M H J, et al.
Publicado: (2023)

Brady- and tachyarrhythmias detected by continuous rhythm monitoring in paroxysmal atrial fibrillation
por: Frausing, Maria Hee Jung Park, et al.
Publicado: (2023)

Gut-microbe derived TMAO and its association with more progressed forms of AF: Results from the AF-RISK study
por: Nguyen, B.O., et al.
Publicado: (2021)

Rate control with calcium channel blockers versus betablockers in patients with paroxysmal and persistent atrial fibrillation - data from the AFFIRM trial
por: Koldenhof, T, et al.
Publicado: (2023)

Cardioversion strategy impacts quality of rate control during recurrences of atrial fibrillation
por: Van Der Velden, R, et al.
Publicado: (2023)

Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study
por: Kloosterman, Mariëlle, et al.
Publicado: (2019)

Non vitamin K anticoagulation drugs will win the race
por: Van Gelder, I. C., et al.
Publicado: (2016)

Effects of a simple cardiac rehabilitation program on improvement of self-reported physical activity in atrial fibrillation – Data from the RACE 3 study
por: Nguyen, Bao Oanh, et al.
Publicado: (2020)

Mapping and Imaging in Non-paroxysmal AF
por: Ghannam, Michael, et al.
Publicado: (2019)

Paradigm shifts in pathophysiology and management of atrial fibrillation—a tale of the RACE trials in the Netherlands
por: Crijns, H. J. G. M., et al.
Publicado: (2020)

Opposite evolution on voltage and thickness from paroxysmal to persistent AF
por: Silva Garcia, E, et al.
Publicado: (2023)

Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study
por: Al-Jazairi, Meelad I H, et al.
Publicado: (2021)

Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial
por: Nguyen, Bao Oanh, et al.
Publicado: (2021)

Extended ECG Improves Classification of Paroxysmal and Persistent Atrial Fibrillation Based on P- and f-Waves
por: Zink, Matthias Daniel, et al.
Publicado: (2022)

Incidence and outcome of atrial fibrillation: diversity throughout Europe
por: Rienstra, Michiel, et al.
Publicado: (2021)

Diagnostic values of different ECG durations in paroxysmal AF diagnosis
por: Li, Qian, et al.
Publicado: (2021)

Contemporary management of patients with atrial fibrillation in the Netherlands and Belgium: a report from the EORP-AF long-term general registry
por: Erküner, Ö., et al.
Publicado: (2021)

Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation
por: Chu, Gordon, et al.
Publicado: (2020)

Prevalence and Incidence of Atrial Fibrillation in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: (Additive) Value of Implantable Loop Recorders
por: Gorter, Thomas M., et al.
Publicado: (2023)

Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure
por: Brandes, Axel, et al.
Publicado: (2020)

Atrial fibrillation and heart failure temporality: does it matter?
por: Van Deutekom, Colinda, et al.
Publicado: (2022)

Role of diagnosis-to-ablation time in paroxysmal atrial fibrillation: preliminary results of the MULTI AF trial
por: Rossi, L, et al.
Publicado: (2023)

Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events
por: Loeffen, Rinske, et al.
Publicado: (2016)

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands
por: ten Cate, V., et al.
Publicado: (2016)

Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
por: Henskens, Yvonne M. C., et al.
Publicado: (2018)

Thrombin generation by calibrated automated thrombography in goat plasma: Optimization of an assay
por: D'Alessandro, Elisa, et al.
Publicado: (2021)

Erratum to: The Global Anticoagulant Registry in the FIELD – Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands
por: ten Cate, V., et al.
Publicado: (2016)

Safety and efficacy of cryoballoon ablation for the treatment of paroxysmal and persistent AF in a real‐world global setting: Results from the Cryo AF Global Registry
por: Chun, Kyoung Ryul Julian, et al.
Publicado: (2021)

Radiofrequency Versus Cryoballoon Catheter Ablation for Paroxysmal Atrial Fibrillation: Durability of Pulmonary Vein Isolation and Effect on Atrial Fibrillation Burden: The RACE-AF Randomized Controlled Trial
por: Sørensen, Samuel K., et al.
Publicado: (2021)

Clinical Characteristics To Guide The Extent Of Ablation In Paroxysmal AF Patients: Discovering An Old Science
por: Brooks, Anthony G, et al.
Publicado: (2009)

Changes in LA volume and diameter correlate with mechanisms of recurrence after paroxysmal AF ablation
por: Buffle, Eric, et al.
Publicado: (2022)

Update on management of atrial fibrillation in heart failure: a focus on ablation
por: Mulder, Bart A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jk4rn24e1va1ouua7jmnvcmrtr